Views & Analysis Expanding data sources: faster drug development? Using advanced technology and the skills of the data scientist to manage data from diverse sources.
News Biogen swoops on Apellis with $5.6bn offer In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
